Farallon Capital Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Farallon Capital Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,440,000	Closed	-$69.1M	–	137
2020 Q1	$69.1M	Buy	1,440,000 +251,900	+21%	+$11.7M	0.59%	34
2019 Q4	$55.8M	Buy	+1,188,100	New	+$52.5M	0.38%	52

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Farallon Capital Management's RARX Position: Q2 2020 in Review

Farallon Capital Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 1,440,000 shares — an estimated $69.1M sold.

Farallon Capital Management first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $69.1M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Farallon Capital Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Farallon Capital Management sold 1,440,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $69.1M.
Farallon Capital Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
Farallon Capital Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $69.1M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.